From: Role of PET/CT in initial evaluation of lymphoma patients
Partial response | Complete response | Stable disease | Progressive disease | P value | |
---|---|---|---|---|---|
Baseline SUV | |||||
Median | 12.6 | 9.7 | 3.4 | 2.7 | P = 0.0004A |
IQR | 9–15.8 | 5.6–14 | 2.8–4.2 | 1.8–16.4 | |
Range | 3.1–29 | 1.3–25 | 2.5–4.6 | 1.8–16.4 | |
Post-treatment SUV | |||||
Median | 3.3 | 0 | 3 | 6.3 | P < 0.000001B |
IQR | 2–4.8 | 0–0 | 2.4–3.7 | 2.7–22.1 | |
Range | 1.18–8.2 | 0–0 | 1.8–4.5 | 2.7–22.1 | |
∆SUV (%) | |||||
Median | 74.5 | 100 | 11.9 | − 53.4 | P < 0.000001 |
IQR | 65.3–80.8 | 100–100 | 1.1–24.8 | − 137.7 to 35.1 | |
Range | 41.9–87.3 | 100–100 | 0–28 | − 137.7 to − 35.1 | |
Baseline MTV | |||||
Median | 29.8 | 5.8 | 42.5 | 31.2 | P = 0.011C |
IQR | 4.8–78 | 2.8–23.1 | 6.9– 264.5 | 2.9–39 | |
Range | 1.13–215 | 1.13–182 | 2.8–455 | 2.9–39 | |
Post-treatment MTV | |||||
Median | 2.6 | 0 | 32.7 | 38.4 | P < 0.000001D |
IQR | 1–6 | 0–0 | 6.3–238.2 | 5.1–47.7 | |
Range | 0.5–92 | 0–0 | 1.6–422 | 5.1–47.7 | |
∆MTV (%) | |||||
Median | 75.5 | 100 | 16.95 | − 23.1 | P < 0.000001 |
IQR | 55.8–94.4 | 100–100 | 3.7–34.8 | − 76.2 to − 22.4 | |
Range | 39.9–99.4 | 100–100 | 0–42.9 | − 76.2 to − 22.4 | |
Baseline TLG | |||||
Median | 250 | 25 | 100 | 49.1 | P = 0.037E |
IQR | 24.7–1081 | 11.3–173.7 | 13.5–685.5 | 4.7–306.5 | |
Range | 6.8–2038 | 2.6–1804 | 4–1194 | 4.7–306.5 | |
Post-treatment TLG | |||||
Median | 6.5 | 0 | 61 | 60.4 | P < 0.000001F |
IQR | 2.3–15.3 | 0–0 | 12.4–564.5 | 17.1–528.2 | |
Range | 0.8–117.6 | 0–0 | 1.8–1030 | 17.1–528.2 | |
∆TLG (%) | |||||
Median | 91.4 | 100 | 28.9 | − 65.5 | P < 0.000001 |
IQR | 85.6–99.2 | 100–100 | 6.9–49.6 | − 263.8 to − 23 | |
Range | 71.2–99.9 | 100–100 | 0–55 | 263.8 to − 23 |